Cochlear has confirmed that its hearing implant systems will continue to enter the United States duty-free after the U.S. government’s final Section 301 determination, preserving the tariff-free status under the Harmonized Tariff Schedule. The decision removes potential import duty costs and supports Americans’ access to cochlear implants, which Cochlear notes benefits a small but growing population of users. Company executives highlighted the ongoing importance of expanding access to hearing solutions and engaging with global trade and policy efforts as the clinical need for implants rises. Analysts and market observers have noted the favorable tariff outcome as a positive factor for Cochlear’s US market access and pricing, with Cochlear positioning itself as a leader in the field. The development follows a broader emphasis on ensuring imports produced without forced labor can flow freely into the United States, maintaining stability for Cochlear’s supply chain and long-term growth plans.